Procognia Ltd. Company Profile

Background

Overview

Procognia Ltd. is a biotechnology company specializing in glycobiology and glycoanalysis, focusing on the analysis of glycosylation patterns in proteins. Established in 2000 and publicly traded on the Tel Aviv Stock Exchange (TASE: PRCG), the company has developed proprietary technologies to enhance the development and manufacturing of biopharmaceuticals.

Mission and Vision

Procognia's mission is to advance the understanding and application of glycosylation in biopharmaceuticals, aiming to improve the efficacy, safety, and biosimilarity of therapeutic proteins. The company's vision is to be a leading provider of glycoanalysis solutions, facilitating the development of high-quality biologic drugs.

Primary Area of Focus

The company specializes in glycoanalysis, offering services that include N-linked and O-linked glycan analysis, profiling and quantitative analysis of sialic acid, quantitative monosaccharide analysis, and high-throughput glycosylation analysis using its proprietary GlycoScope™ technology.

Industry Significance

Procognia plays a crucial role in the biopharmaceutical industry by providing essential tools for analyzing glycosylation patterns, which are vital for the development of effective and safe therapeutic proteins. Its technologies support the optimization of glycosylation profiles, contributing to the success of biologic drugs.

Key Strategic Focus

Core Objectives

Enhancing Biopharmaceutical Development: Improving the quality and efficacy of therapeutic proteins through advanced glycoanalysis.

Expanding Service Offerings: Broadening the range of glycoanalysis services to meet the evolving needs of the biopharmaceutical industry.

Specific Areas of Specialization

Glycoanalysis Services: Providing comprehensive glycosylation analysis to support the development and manufacturing of biopharmaceuticals.

Biosimilar Development: Collaborating with partners to enhance the production and quality of biosimilars.

Key Technologies Utilized

GlycoScope™ Technology: A proprietary high-throughput lectin array-based platform for glycoanalysis.

Primary Markets Targeted

Biopharmaceutical Companies: Offering glycoanalysis services to support drug development and manufacturing.

Biosimilar Manufacturers: Providing technologies to improve the production and quality of biosimilars.

Financials and Funding

Funding History

Initial Funding: In April 2002, Procognia completed a $14.3 million financing round led by Apax Partners, valuing the company at approximately $22 million post-money.

Acquisition: In January 2003, Procognia acquired Sense Proteomic Ltd., a move aimed at advancing its drug discovery capabilities.

Recent Funding Rounds

Specific details on recent funding rounds are not publicly disclosed.

Notable Investors

Apax Partners: Led the $14.3 million financing round in 2002.

Evergreen Partners: Participated in the 2002 financing round.

Vitalife: Participated in the 2003 financing round.

Intended Utilization of Capital

The funds raised have been utilized to support research and development activities, expand service offerings, and enhance the company's technological capabilities in glycoanalysis.

Pipeline Development

Key Pipeline Candidates

GlycoScope™ Technology: An advanced glycoanalysis platform designed to support the development and manufacturing of biopharmaceuticals.

Stages of Development

Commercialization: GlycoScope™ technology is actively marketed and utilized by biopharmaceutical companies for glycoanalysis.

Target Conditions

Biopharmaceutical Development: Enhancing the quality and efficacy of therapeutic proteins.

Biosimilar Production: Improving the production and quality of biosimilars.

Anticipated Milestones

Market Expansion: Increasing adoption of GlycoScope™ technology among biopharmaceutical companies.

Service Diversification: Expanding the range of glycoanalysis services offered to meet industry needs.

Technological Platform and Innovation

Proprietary Technologies

GlycoScope™ Technology: A high-throughput lectin array-based platform for glycoanalysis, enabling detailed analysis of glycosylation patterns in proteins.

Significant Scientific Methods

Lectin Array-Based Analysis: Utilizing lectin arrays to identify and characterize glycosylation patterns in proteins.

High-Throughput Screening: Enabling rapid analysis of glycosylation profiles to support biopharmaceutical development.

Leadership Team

Key Executives

Dr. Ruth Ben Yakar: CEO, leading the company's strategic direction and operations.

Ron Long: Chairman and CEO, appointed in 2002, formerly CEO of Amersham Pharmacia Biotech.

Professional Backgrounds

Dr. Ruth Ben Yakar: Experienced in glycobiology and biopharmaceutical analytics, overseeing the company's research and development initiatives.

Ron Long: Brings extensive experience in the biotechnology industry, having previously served as CEO of Amersham Pharmacia Biotech.

Key Contributions

Dr. Ruth Ben Yakar: Instrumental in advancing Procognia's glycoanalysis technologies and expanding its service offerings.

Ron Long: Played a pivotal role in securing significant funding and strategic partnerships to support the company's growth.

Competitor Profile

Market Insights and Dynamics

The glycoanalysis market is integral to the biopharmaceutical industry, with increasing demand for technologies that can optimize glycosylation profiles in therapeutic proteins. Procognia competes with other companies offering glycoanalysis services and technologies.

Competitor Analysis

Enzo Biochem: Provides a range of biomedical products and services, including glycoanalysis.

deltaDOT: Specializes in capillary electrophoresis technology for biomolecule analysis.

Athena Environmental Sciences: Offers tools and services for protein production and purification.

Strategic Collaborations and Partnerships

CTC Laboratory System Corporation (CTCLS): Entered into a distribution and marketing license agreement in 2011 to promote GlycoScope™ in Japan.

QIAGEN N.V.: Entered into a marketing and licensing agreement in 2005 to combine QIAGEN's products with Procognia's glycoanalysis technology.

Operational Insights

Procognia differentiates itself through its proprietary GlycoScope™ technology, offering high-throughput glycoanalysis solutions that are crucial for the development and manufacturing of biopharmaceuticals. Strategic partnerships have expanded its market reach and enhanced its technological capabilities.

Strategic Opportunities and Future Directions